Cantor Fitzgerald Initiates Spero Therapeutics Coverage With Overweight Rating
Cantor Fitzgerald initiated coverage of Spero Therapeutics with an Overweight rating and a $6 price target. The target implies 426.3% upside from the Oct. 27 close of $1.14.